The U.S. Food and Drug Administration (FDA) has expanded the approval of Furoscix® (furosemide injection) to include pediatric patients weighing 43 kilograms (about 95 pounds) or more, marking a significant milestone in the treatment of fluid overload associated with chronic heart failure (CHF) and chronic kidney disease (CKD). This decision opens the door to more flexible, at-home treatment options for a carefully defined pediatric population and reinforces the growing role of drug-device combinations in modern care delivery.
Announced by MannKind Corporation in December 2025, the approval reflects not only progress in pediatric access to advanced therapies but also broader innovation in how diuretic treatments may be delivered outside hospital settings.
This article breaks down what Furoscix is, why this FDA approval matters, how it impacts pediatric and adult care, and what lies ahead with the investigational Furoscix ReadyFlow™ Autoinjector.
Furoscix is a subcutaneous formulation of furosemide, a loop diuretic that has been used for decades to manage edema (fluid overload) in patients with heart failure and kidney disease. Unlike traditional oral or intravenous (IV) furosemide, Furoscix is delivered via an On-body Infusor, allowing patients to receive IV-equivalent diuretic therapy outside of a hospital or infusion center.
Furoscix is indicated for the treatment of edema related to:
With the latest FDA approval, Furoscix is now indicated for:
Pediatric patients with heart or kidney disease often face limited outpatient treatment options when fluid overload worsens. Hospital admissions for IV diuretics are common, disruptive, and costly—not only financially but emotionally for children and families.
By approving Furoscix for pediatric patients who meet the weight threshold, the FDA has enabled:
This approval also fulfills post-marketing requirements under the Pediatric Research Equity Act (PREA), demonstrating regulatory confidence in the safety and effectiveness of the therapy for this specific population.
The Furoscix On-body Infusor is a wearable delivery system that administers furosemide subcutaneously over a controlled period. The device is designed for home use, with built-in alerts to notify patients if infusion is interrupted.
However, patients must be trained to monitor alarms and ensure proper device use, as movement or fluid contact can interrupt infusion.
In addition to the pediatric approval, MannKind announced that the FDA has accepted for review a supplemental New Drug Application (sNDA) for the Furoscix ReadyFlow Autoinjector, an investigational device that could further transform diuretic therapy.
If approved, ReadyFlow would:
The FDA has assigned a PDUFA target action date of July 26, 2026.
| Feature | On-Body Infusor | ReadyFlow Autoinjector* |
|---|---|---|
| Delivery Time | Several minutes | <10 seconds |
| FDA Approval Status | Approved (adults & pediatric ≥43 kg) | Under FDA review |
| Setting | At home | At home |
| Drug Strength | 80 mg/10 mL | 80 mg/mL |
| Ease of Use | Wearable device | Single injection |
| Potential Impact | Reduced hospital visits | Rapid intervention, greater convenience |
*ReadyFlow Autoinjector is investigational and not yet FDA-approved.
MannKind also disclosed that the U.S. Patent and Trademark Office (USPTO) issued five new U.S. patents covering the Furoscix ReadyFlow Autoinjector. These patents protect:
If approved, these patents would be listed in the FDA’s Orange Book and could provide protection through 2040, strengthening MannKind’s competitive position in the heart failure and CKD markets.
Like all loop diuretics, Furoscix carries important safety considerations.
Furoscix should not be used in patients with:
Patients receiving Furoscix should undergo regular monitoring of:
The most common adverse reactions reported in clinical trials were injection-site and skin reactions, including redness, bruising, swelling, and pain.
The expansion of Furoscix into pediatric care and the potential approval of ReadyFlow reflect a broader shift toward hospital-at-home models and patient-centric drug delivery.
For healthcare providers, these innovations may help optimize resource utilization while maintaining clinical effectiveness.
MannKind Corporation (Nasdaq: MNKD) is a biopharmaceutical company focused on cardiometabolic and orphan lung diseases. With deep expertise in drug-device combinations, the company aims to deliver therapies that integrate seamlessly into patients’ daily lives. Its portfolio spans diabetes, pulmonary hypertension, and fluid overload associated with heart and kidney disease.
The FDA’s approval of Furoscix for pediatric patients weighing 43 kg or more represents a meaningful step forward in expanding access to advanced diuretic therapy beyond traditional hospital settings. Combined with the ongoing review of the Furoscix ReadyFlow Autoinjector and strengthened patent protection, MannKind is positioning Furoscix as a cornerstone therapy in the evolving management of fluid overload.
As regulatory decisions unfold in 2026, Furoscix may continue to redefine how patients—both young and adult—manage chronic heart and kidney conditions from the comfort of home.
This article is for educational and informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding medical conditions, medications, or treatment decisions. Drug indications, warnings, and approvals are subject to change based on ongoing regulatory review.
Most Accurate Healthcare AI designed for everything from admin workflows to clinical decision support.